- Home
- TERN vs AUTL Comparison
TERN vs AUTL Comparison
Compare TERN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- AUTL
- Stock Information
- Founded
- TERN 2017
- AUTL 2014
- Country
- TERN United States
- AUTL United Kingdom
- Employees
- TERN N/A
- AUTL N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TERN Health Care
- AUTL Health Care
- Exchange
- TERN Nasdaq
- AUTL Nasdaq
- Market Cap
- TERN 634.5M
- AUTL 625.4M
- IPO Year
- TERN 2021
- AUTL 2018
- Fundamental
- Price
- TERN $7.30
- AUTL $1.32
- Analyst Decision
- TERN Buy
- AUTL Strong Buy
- Analyst Count
- TERN 6
- AUTL 5
- Target Price
- TERN $13.99
- AUTL $9.12
- AVG Volume (30 Days)
- TERN 1.1M
- AUTL 4.2M
- Earning Date
- TERN 11-11-2025
- AUTL 11-11-2025
- Dividend Yield
- TERN N/A
- AUTL N/A
- EPS Growth
- TERN N/A
- AUTL N/A
- EPS
- TERN N/A
- AUTL N/A
- Revenue
- TERN N/A
- AUTL $29,934,000.00
- Revenue This Year
- TERN N/A
- AUTL $641.63
- Revenue Next Year
- TERN N/A
- AUTL $109.21
- P/E Ratio
- TERN N/A
- AUTL N/A
- Revenue Growth
- TERN N/A
- AUTL 185.17
- 52 Week Low
- TERN $1.87
- AUTL $1.11
- 52 Week High
- TERN $10.70
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TERN 52.85
- AUTL 26.05
- Support Level
- TERN N/A
- AUTL $1.30
- Resistance Level
- TERN $7.67
- AUTL $1.46
- Average True Range (ATR)
- TERN 0.41
- AUTL 0.09
- MACD
- TERN -0.32
- AUTL 0.01
- Stochastic Oscillator
- TERN 93.83
- AUTL 7.25
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.